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 •  Pembrolizumab (PBM) is a monoclonal antibody 
targeted against program cell death-1 (PD-1) 
proteins on cell surfaces, thus inhibiting their 
interaction and allowing the body’s immune 
system to recognize and destroy malignant cells1
 •  PBM was initially FDA approved in 2014 for 
the treatment of advanced melanoma however 
as of May 2017 has been approved for the 
initial treatment of any solid metastatic or non-
resectable tumors with specific genetic mutations2
 •  Common side effects of this medication fatigue, 
pruritus, anorexia, fever, and diarrhea2
   −  However, serious side effects such as autoimmune 
pneumonitis, hepatitis, colitis, and pancreatitis 
have been reported as the molecular “brakes” are 
removed from the immune system2
 •  We describe a case in which a patient was found 
to develop a secondary primary malignancy while 
enrolled in a clinical trial evaluating the effect of 
PBM for adenoid cystic carcinoma 
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 •  76-year-old female with no medical history presented with right ear pain and hearing loss
 •  Head CT and MRI revealed mixed lytic and sclerotic temporal and maxillary bone lesions suggestive of a neoplastic 
process
 •  Surgical biopsy of the maxillary sinus diagnosed adenoid cystic carcinoma. PET scan initially negative for 
metastatic disease
 •  She underwent right maxillary sinus resection followed by adjunctive radiotherapy
 •  Serial imaging 3 years later suggested reoccurrence within her right orbit which was confirmed by biopsy
 •  Rather undergo repeat surgery, she was enrolled in a clinical trial with PBM
 •  Following her 4th dose (3rd month) she complained of abdominal pain. CT noted intra- and extra-hepatic biliary 
dilatation despite normal chemistries.
 •  EUS demonstrated 3.2 x 2.5cm mass within the pancreatic head (Figure 1) with FNA biopsies consistent with 
moderately differentiated adenocarcinoma which was not pathologically associated with her head and neck cancer. 
 •  She currently continues to undergo immunotherapy treatment
 •  PBM is a novel immunotherapy agent which has gained significant 
interest with recent FDA approval for the treatment of various 
malignancies
 •  Presented is a case in which a patient developed a pancreatic 
malignancy while being treated with PBM for her adenoid cystic 
carcinoma
 •  The incidence of pancreatic cancer among patients treated with 
PBM is unclear
 •  However given the recent FDA approval of PBM in solid tumors 
(including pancreatic malignancies), this may ultimately be a 
unfortunate coincidence
 •  More data is required to identify the long-term risks of PBM, 
specifically the incidence of new onset malignancies while on 
therapy
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Figure 1: EUS of the pancreatic head demonstrating a large hypoechoic mass.
